Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Lowers Price Target to $20
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and lowers the price target from $30 to $20.
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and lowers the price target from $30 to $20.